Time to hop on board Acasti Pharma, says Mackie Research

Jul 02 17:07 2019 Print This Article

With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for liftoff, says Mackie Research Capital Corporation analyst André Uddin. On Thursday, Uddin reiterated his “Speculative Buy” rating and $8.70 target price for Acasti, representing a projected 12-month return of 469 per cent […]

The post Time to hop on board Acasti Pharma, says Mackie Research appeared first on Cantech Letter.

Read More

About Article Author

Cantech Letter

Founded in 2008 by Nick Waddell, Cantech Letter is an online magazine focusing on Canadian technology. The site has grown into one of the most popular and respected financial sites in Canada, and was described by Canadian Business Magazine as “one of Canada’s premier technology newsletters”. Waddell, who is Senior Editor, is routinely called on by the mainstream media for perspective on Canadian technology, and has been featured on BNN, CTV News Channel, and the CBC program “The Lang and O’Leary Exchange” in addition to mainstream print media such as The Guardian, The International Business Times, The Globe and Mail, Macleans, The Waterloo Record , Canadian Business, Slate, and Business Insider. You can email Nick at nick@cantechletter.com Cantech Letter is focused on those companies listed on the TSX and TSXV Technology, Cleantech and Life Sciences Sectors. Each year we present the Cantech Letter Awards, which honor Canada’s Top Technology Stock and Top Technology Stock Executive.

Related Items

The Ten Best Performing Canadian Life Sciences Stocks of 2019

It was another up and down year for Canadian Life Sciences stocks. In 2018, the downfall of the sector came in the last couple of months. A year later, it happened early when cannabis stocks began to collapse. (The S&P TSX Pharma & Biotech Index lost almost half of its value between March and the [ ...

Acasti Pharma placed under review by Mackie Research Capital

Disappointing results for its lead product candidate CaPre have led Mackie research capital analyst André Uddin to place Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) under review. This morning, Acasti reported topline results for Trilogy 1 Phase Three trail of CaPre that saw th ...

Tech Talk for Thursday January 9th 2020

Pre-opening Comments for Thursday January 9th U.S. equity index futures were higher this morning. S&P 500 futures were up 11 points in pre-opening trade. Index futures were virtually unchanged following release of Weekly Initial Jobless Claims at 8:30 AM EST. Consensus was unchanged from the previo ...

Acasti Pharma keeps “Top Pick” Status at Echelon for 2020

Quebec-based omega-3 drug developer Acasti Pharma (Acasti Pharma Stock Quote, Chart, News TSXV:ACST) is keeping its “Top Pick” status from Echelon Wealth Partners analyst Douglas Loe. In a research update to clients Tuesday, Loe maintained his “Speculative Buy” rating and $4.00 price target ...

Tech Talk for Monday January 6th 2020

  The Bottom Line The intermediate uptrend in world markets stalled on Friday on news of rising conflict in the Middle East.   Observations Seasonal influences this year continue to follow their historic pattern. Note seasonal charts below showing that most equity markets have a history of weake ...

Canopy Growth will remain a problem for Constellation Brands, this investor says

The write-downs likely aren’t done yet. That’s the takeaway from portfolio manager Jason Mann’s assessment of Constellation Brands (Constellation Brands Stock Quote, Chart, News NYSE:STZ) and its troubled investment in cannabis company Canopy Growth (Canopy Growth Stock Quote, Chart, News TSX ...

The worst is over for Organigram, says Raymond James

Operational excellence was the takeaway from Organigram Holdings (Organigram Holdings Stock Quote, Chart, News TSX:OGI) in its latest quarter, according to Raymond James analyst Rahul Sarugaser, who in an update to clients on Wednesday raised his rating for OGI from “Market Perform 3” to “Out ...

PI Financial cuts price target on Aphria

Following the company’s second quarter results, PI Financial analyst Jason Zandberg has cut his price target on Aphria (Aphria Stock Quote, Chart, News TSX:APHA), though the analyst has maintained his “Buy” rating on the stock. On Tuesday, Aphria reported its Q2, 2020 results. The company los ...

10 pot stocks that actually went up in 2019

2019 was, to say it mildly, not a good for Canada’s cannabis sector. The feel good story that was Canada’s leadership role in the space turned into a horror show. Just about every name brand in the sector took double-digit losses? Canopy Growth? Down 27 per cent. CannTrust? Down 76 per cent. Or ...